Company Overview - Medline is a medical supply company that manufactures and distributes products such as masks, gowns, and lab kits [3] - The company was taken private in 2021 by a consortium of private equity firms, including Blackstone, Carlyle, and Hellman & Friedman, marking the largest leveraged buyout (LBO) post-financial crisis [3][4] IPO Details - The IPO is expected to price tonight and could be one of the largest debuts in the public markets this year, potentially valued at $55 billion, which is over $20 billion higher than the acquisition price by its sponsors [1][4] - The IPO guidance suggests pricing toward the high end of the range, indicating strong investor interest [2] Business Performance - Medline has demonstrated a resilient business model, with net sales growing each year since its inception in the 1960s at a compound annual growth rate (CAGR) of 18% [4] - The company is expected to benefit from secular tailwinds such as an aging population and the consolidation of healthcare providers [5] Growth Strategy - Medline's growth strategy includes acquiring several companies and continuing this trend to enhance its market position [5] - The concentration within Medline's business and its customer base is viewed as both a potential advantage and a risk factor [6] Market Context - The IPO is seen as a critical test for the IPO market, which has a healthy backlog of deals for 2026, and for the private equity industry, which has faced challenges in finding exits for portfolio companies [4]

Summary of Key Points Core Viewpoint - The article discusses the recent IPO activities, highlighting that 10 new stocks were listed last week, with 9 of them raising over $100 million each. Group 1: Recent IPOs - JM Group (JMG) raised $15 million by issuing 3.75 million shares at $4 per share [1] - Wealthfront (WLTH) raised $485 million by issuing 34.62 million shares at $14 per share [2] - Lumexa Imaging Holdings (LMRI) raised $463 million by issuing 25 million shares at $18.5 per share [2] - Cardinal Infrastructure (CDNL) raised $242 million by issuing 11.5 million shares at $21 per share [2] - SPACs Bluerock Acquisition (BLRKU), Carbon Capital Partner (KBONU), Meshflow Acquisition (MESHU), Daedalus Special Acquisition (DSACU), ITHAX Acquisition III (ITHAU), and Twelve Seas III (TWLVU) raised $150 million, $300 million, $300 million, $225 million, $200 million, and $150 million respectively [2] Group 2: Upcoming IPOs - Andersen Group Inc., a tax consulting firm, plans to go public on December 17, 2025, on the NYSE under the ticker ANDG, aiming to raise approximately $176 million by issuing 11 million shares at $14 to $16 per share [3][6] - Medline Inc., a leading medical supplies manufacturer, plans to go public on December 17, 2025, on NASDAQ under the ticker MDLN, aiming to raise approximately $5.37 billion by issuing 17.9 million shares at $26 to $30 per share [8][11]

Ukraine's health supplies hit in series of Russian strikes on medical warehouses https://t.co/Wnfv1RqG1d ...

Core Insights - SpaceX is planning to raise $30 billion for an initial public offering (IPO) with a valuation of $1.5 trillion, targeting mid- to late 2026 for the launch of this IPO [1] - The IPO market is experiencing a significant rebound, with US IPO volume expected to exceed $40 billion this year, surpassing last year's total [2] - SpaceX is currently the world's most valuable private company, recently valued at $800 million through a secondary share sale, and is expected to be joined by other high-value private companies in the IPO market [3] Group 1 - SpaceX's IPO plans indicate a shift in focus from long-term goals of Martian colonization to immediate financial opportunities in the public market [1] - The anticipated IPO could elevate the overall market for public listings, with Wall Street preparing for an even larger IPO volume in 2026 [2] - Other companies expected to go public next year include York Space Systems, Ethos Technologies, Kraken, and EquipmentShare, but SpaceX's valuation significantly overshadows these potential listings [3] Group 2 - OpenAI, valued at $1 trillion, is also considering an IPO, highlighting a trend of high-value private companies entering the public market [3] - The term "centicorns" refers to private companies valued at $100 billion or more, with several such companies potentially making public market debuts next year [3] - Wall Street could facilitate the entry of approximately $2.9 trillion worth of private companies into public markets, indicating a robust future for IPOs [3]

Medline's IPO and Family Wealth - Medline's IPO is anticipated to be a significant event this winter, potentially valued at up to $55 billion, with the Mills family's remaining stake estimated between $6 billion to $7 billion based on share price projections of $26 to $30 per share [1][2] - The Mills family's total net worth is projected to reach at least $20 billion, combining their stake in Medline and previous earnings from a private equity deal that valued the company at $30 billion [2] Company Performance - Under private equity ownership and the leadership of non-family CEO Jim Boyle, Medline has shown growth, achieving sales of $25.5 billion in 2024 and profits of $1.2 billion [4] Surgical Robotics Investments - Dr. Fred Moll, a pioneer in robotic surgery, has invested around $100 million into next-generation surgical robotics startups, aiming to enhance the capabilities of average surgeons through advanced robotic technology [5][6] - The goal of these investments is to improve medical procedures across various fields, including colonoscopies and heart-valve replacements, utilizing AI to refine surgical techniques [6][7] Forbes Top Hospitals List - Forbes has introduced its inaugural Top Hospitals List for 2026, which aims to provide an unbiased, data-driven evaluation of general acute care hospitals in the U.S. [8] - The list was developed in collaboration with Inovalon and various healthcare experts to assist patients and hospital leaders in assessing healthcare quality [9] Freenome's SPAC Deal - Freenome, a company focused on early cancer detection through blood tests, is going public via a SPAC merger valued at $330 million, which includes a $240 million investment from healthcare investors [10] - The company has partnerships with Roche and Exact Sciences and plans to launch multiple tests by 2026 [10]

Core Insights - The Mills family, founders of Medline, sold a majority stake to private equity in 2021 for $30 billion, but their remaining stake is now valued at $6 billion to $7 billion, contributing to a total estimated net worth of $20 billion for the family [1][2][3] - Medline is preparing for a significant IPO this winter, potentially valued at up to $55 billion, marking it as a major event in the market [1] - The company's sales have surged to $25.5 billion in 2024, an 83% increase from $13.9 billion five years prior, with profits rebounding to $1.2 billion [8] Company Background - Medline was founded in 1910 by A.L. Mills, initially selling butcher's aprons before transitioning to medical supplies after a request from a local hospital seamstress [5] - The company has a history of innovation, including the introduction of the first surgeon's gown with 360-degree coverage and the commercialization of specific fabrics to reduce glare in operating rooms [5] Recent Developments - The Mills family established a family office called Council Ring Capital after the 2021 sale and began stepping back from day-to-day operations in 2023 [3][7] - Jim Boyle became the first non-family CEO of Medline in October 2023, indicating a shift in leadership dynamics [7] - Medline's role in the pandemic response was significant, distributing medical supplies to nursing homes, pharmacies, and 45% of hospital systems nationwide [6]

Private equity-backed Medline is aiming to raise as much as $5.37 billion in its initial public offering in the United States, the medical supplies provider said on Monday. ...

Table of Contents As filed with the Securities and Exchange Commission on December 8, 2025. Registration No. 333-291112 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 2 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Medline Inc. (Exact Name of Registrant as Specified in its Charter) (State or other jurisdiction of incorporation or organization) Delaware 3841 33-1845288 (Primary Standard Industrial Classification Code Number) 3 Lakes Drive (I.R.S. E ...

Core Insights - Brown Advisory's Large-Cap Growth Strategy reported a net return of -0.88% in Q3 2025, underperforming the Russell 1000 Growth Index due to underweighting speculative momentum-driven stocks despite significant exposure to AI [1] - The investor letter highlighted West Pharmaceutical Services, Inc. (NYSE:WST) as a key stock, which experienced a one-month return of 3.26% but a 52-week loss of 10.65% [2] - West Pharmaceutical Services, Inc. rebounded with a 20% stock increase in Q3 2025 following a strong earnings report and the hiring of a new CFO, while also showing consecutive revenue growth in its high-value product segment [3] Company Performance - West Pharmaceutical Services, Inc. reported revenues of $805 million in Q3 2025, reflecting a 5% organic growth [4] - The company's market capitalization stood at $18.554 billion as of December 3, 2025, with shares closing at $284.31 [2] - Despite the positive outlook for West Pharmaceutical Services, some analysts believe that certain AI stocks present greater upside potential and lower downside risk [4] Market Sentiment - TD Cowen initiated coverage on West Pharmaceutical Services with a Buy rating and a target price of $350 [4] - The number of hedge fund portfolios holding West Pharmaceutical Services increased from 46 to 49 in Q3 2025, indicating growing interest among institutional investors [4]

MELBOURNE, Australia and PALM BEACH, Fla., Dec. 02, 2025 (GLOBE NEWSWIRE) -- CYIOS Corp. (OTC: CYIO), a diversified holding company focused on acquiring, building, and scaling high-growth businesses in the medical, technology, and innovation sectors, is pleased to announce the appointment of John O’Shea as its new Chief Executive Officer and Chairman of the Board. A serial entrepreneur, published author, and seasoned senior executive with more than 30 years of experience across finance, technology, educatio ...